Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
Haemophilia is an inherited, serious bleeding disorder where a person’s blood does not clot properly, leading to uncontrolled bleeding, which can occur spontaneously or after minor trauma. It can significantly reduce the quality of life of people affected, as well as their family, friends and caregivers.1 Haemophilia A is the most common form of Haemophilia worldwide.2,3
Prophylaxis is a preventative, regular treatment involving either factor VIII replacement therapies or non-factor therapies like Emicizumab (Hemlibra), with the goal to prevent bleeds and allow people with Haemophilia A to lead active lives and achieve quality of life comparable to non-haemophilic individuals 2.
With updates including a new definition of prophylaxis, changes to protections levels and a new worldwide standard of care, the World Federation of Hemophilia Guidelines 2020 reflect important developments in the management of haemophilia with Hemlibra.4
In Bangladesh, Hemlibra is approved for the following indication(s)5:
Routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adults and children with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
Hemlibra can be used in all age groups.
For more disease and treatment related queries, it is recommended that you discuss with your physicians in details.
In Bangladesh, Hemlibra is available as
30 mg/ml in a single-dose vial
60 mg/0.4 mL in a single-dose vial
105 mg/0.7 mL in a single-dose vial
150 mg/mL in a single-dose vial
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References
Flood E, et al. Illustrating the impact of mild/moderate and severe haemophilia on health-related quality of life: hypothesised conceptual models. European Journal of Haematology 2014; 93: Suppl. 75, 9–18
Srivastava, A, Santagostino, E, Dougall, A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020: 26 (Suppl 6): 1‐ 158
Iorio A et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Ann Intern Med 2019 Oct 15;171(8):540-546.
Hemlibra Product Information_BD RO5534262_March 2022
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.